Cone-Rod Dystrophy clinical trials at UCSF
2 research studies open to eligible people
Cone-rod dystrophy is a genetic eye disorder affecting vision. UCSF is exploring treatments that may restore sight using cone optogenetics and examining new drugs for ABCA4-related retinopathies. These studies aim to understand how these treatments affect vision in patients with loss of cone-rod function.
ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
open to eligible people ages 18 years and up
This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.
San Francisco, California and other locations
EyeConic: Qualification for Cone-Optogenetics
open to all eligible people
This study aims to prepare for the first-in-human clinical trial of cone optogenetics vision restoration. As a first step, this worldwide multicenter ocular imaging study (EyeConic Study) is performed to identify eligible patients.
San Francisco, California and other locations
Our lead scientists for Cone-Rod Dystrophy research studies include Jacque Duncan.
Last updated: